Table 2.
Tenofovir | Efavirenz | Rilpivirine | Etravirine | Darunavir/r | Atazanavir/r | Lopinavir/r | Fosamprenavir/r | Ritonavir | INSTIa | Maraviroc | |
---|---|---|---|---|---|---|---|---|---|---|---|
Sofosbuvir | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ |
Simeprevir | √ | X | √ | X | X | X | X | X | X | √ | √ |
Telaprevir | √ | ↑ | √ | √ | X | √ | X | X | ± | √ | ↕ |
Boceprevir | √ | X | √ | X | X | X | X | X | X | √ | ↕ |
Daclatasvir | √ | ↑ | √ | --- | ↓ | ↓ | ↓ | ↓ | ↓ | √ | √ |
Ledipasvir | √b | √ | √ | --- | Xb | Xb | Xb | X | Xb | √ | --- |
Grazoprevir | √ | --- | --- | --- | X | X | X | X | X | √ | --- |
Elbasvir | √ | X | --- | --- | X | X | X | X | X | √ | --- |
3Dc | √ | X | X | --- | --- | √ | X | --- | ± | √ | --- |
√, Co-administered without dose adjustment; X, cannot be co-administered; ↑, need to increase DAA dosage when co-administered; ↓, need to decrease DAA dosage when co-administered; ↕, need to decrease maraviroc dosage when co-administered; dashed bar, no data available; ±, varies based on protease inhibitor.
INSTI, integrase inhibitor, not including cobicistat/elvitegravir.
Ledipasvir can increase tenofovir levels, boosted PIs with tenfovir is not recommended.
Combination of paritaprevir/r-ombitasvir and dasabuvir.